Agios Pharmaceuticals IncAGIO
ASignal's systematic analysis rates AGIO as Neutral.
Reflects the latest available analysis · analyzed Aug 22, 2026
The case on AGIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (259.3% YoY)
- Low debt-to-equity ratio (0.03x)
- High cash reserves ($617.58M cash, current ratio 10.22x)
- Positive price momentum (above 20-day SMA and Bollinger middle band)
- Negative operating and gross margins (operating margin: -247.07%, gross margin: -270.79%)
- Negative free cash flow and operating cash flow
- Negative forward P/E and EV/EBITDA suggesting unprofitability
- No Reddit mentions indicating low retail interest
- Overbought RSI at 65.76
See the full verdict on AGIO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AGIO
Most investors never get a second opinion, let alone several. ASignal runs AGIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.